Psoriasis – Current Treatment – Current Treatment: Physician Insights – Psoriasis (EU5)
The psoriasis treatment landscape has significantly evolved in the past few years. A plethora of psoriasis treatments are available in the EU5, ranging from topical agents to conventional systemic therapies (e.g., methotrexate, cyclosporine), biologics, and oral targeted therapies (e.g., Amgen’s Otezla, Bristol Myers Squibb’s Sotyktu). The availability of biosimilars of adalimumab and ustekinumab further expands dermatologists’ treatment armamentarium. However, the abundance of options has increased the complexity of physicians’ prescribing decisions. In this report, we offer insight into dermatologists’ prescribing patterns, attitudes and perceptions, and current and anticipated use of various products. We also offer insight on the perceived advantages and disadvantages of these products, as well as the sales and messaging efforts of key market players.
Questions answered
- Which drugs are the patient-share leaders in different lines of therapy? How are Otezla and Sotyktu positioned in surveyed physicians’ psoriasis treatment algorithm?
- What are the most influential drivers of treatment selection, and under which scenarios do/will physicians prescribe ustekinumab biosimilars and Bimzelx?
- How long do patients stay on a therapy? What factors drive therapy discontinuation and switching?
- How and why has dermatologists’ prescribing changed in the past year? What changes are they anticipating in the coming year?
Markets covered: France, Germany, Italy, Spain, and the United Kingdom
Primary research: 250 dermatologists completed the survey. Of these physicians, 50 were in France, 50 in Germany, 50 in Italy, 50 in Spain, and 50 in the United Kingdom. The survey was fielded in March 2025.
Key companies: AbbVie, Johnson & Johnson Innovative Medicine, Eli Lilly, UCB, Amgen, Bristol Myers Squibb
Key drugs: Humira, Stelara, biosimilar ustekinumab, Taltz, Bimzelx, Tremfya, Skyrizi, Otezla, Sotyktu
Product description
Through survey data from EU5 physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:
- Understand the treatment landscape for a disease and how physicians make prescribing decisions.
- Evaluate the drivers and obstacles that influence treatment selection.
- Analyze your brand’s performance from the physician perspective to enhance or defend your competitive position.
- Create impactful messaging for physicians by identifying brand differentiators and understanding what motivates prescribing behaviors.
